Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alicaforsen · 4 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Alicaforsen | DRUG | - |
Inclusion Criteria 1. Age \>/= 12 years 2. Weight \>/= 36 kg 3. CDAI score of 220 - 400 4. Documentation of Crohn's disease activity by endoscopy, biopsy or imaging in the last 2 years 5. No TNF-α inhibitor treatment for three months prior to first study drug infusion Exclusion Criteria 1. Known ...
Top 15 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 5 | PHASE3 | Duvakitug, balinatunfib, Brivekimig |
| AbbVie, Inc. | ABBV | 16 | PHASE3 | Upadacitinib, Risankizumab, Lutikizumab, Trosunilimab, ABBV-8736 |
| Eli Lilly and Company | LLY | 7 | PHASE3 | Mirikizumab, Tirzepatide, LY4395089, MORF-057 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 15 | PHASE3 | Vedolizumab, Zasocitinib, Darvadstrocel |
| Johnson & Johnson | JNJ | 24 | PHASE3 | Ustekinumab, Guselkumab, JNJ-78934804, Golimumab, Icotrokinra |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Spyre Therapeutics, Inc | SYRE | 2 | PHASE2 | SPY001, SPY002, SPY003 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Shattuck Labs, Inc. | STTK | 1 | PHASE2 | SL-325 |
| AgomAb Therapeutics NV ADR | AGMB | 2 | PHASE2 | Ontunisertib |
| Hoffmann-La Roche | RHHBY | 1 | PHASE2 | Afimkibart |
| Pfizer Inc. | PFE | 1 | PHASE2 | Etrasimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
Alicaforsen is an investigational RNA therapy developed for inflammatory bowel disease, specifically Crohn's disease and ulcerative colitis. It has been studied in clinical trials for patients with active forms of these gastrointestinal conditions. It is not approved for commercial use and remains in clinical development.
Alicaforsen targets ICAM1, also known as intercellular adhesion molecule 1. It is an antisense inhibitor, meaning it is designed to reduce production of the ICAM1 protein. ICAM1 is involved in the inflammatory process, which is the rationale for studying alicaforsen in inflammatory bowel disease.
Alicaforsen is being developed by Ionis Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker symbol IONS. Ionis is the sponsor of the clinical trials evaluating alicaforsen in Crohn's disease and ulcerative colitis.
Alicaforsen has reached Phase 3 clinical development. Two Phase 3 trials were conducted in patients with active Crohn's disease, and earlier Phase 2 studies were run in ulcerative colitis. The drug is investigational and has not been approved by the FDA.
Alicaforsen has been studied in four registered trials. The Phase 3 Crohn's disease studies are NCT00048295, run in Europe, and NCT00048113, run in the United States and Canada, each enrolling 150 patients. The ulcerative colitis Phase 2 studies are NCT00063830 and NCT00063414.
Yes, alicaforsen is also known as ISIS 2302. The earlier clinical trials for ulcerative colitis and Crohn's disease were registered and titled under the ISIS 2302 name, so searches for either term refer to the same antisense drug candidate developed by Ionis Pharmaceuticals.